

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jay A. Goldstein, Michael Rothman and Whe-Yong Lo

Serial No.: 10/691,928

Art Unit: 1616

Filed: October 23, 2003

Examiner: Nathan W. Schlientz

For: *ANTIFUNGAL FORMULATIONS*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. § 1.56 and 37 C.F.R. § 1.97,

Applicants submit a Supplemental Information Disclosure Statement, including one (1) page of Form PTO-1449 and copies of the five (5) documents cited therein.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(d) after an Appeal Brief. The Commissioner is authorized to charge \$180.00, the fee set forth under 37 C.F.R. § 1.17(p), to Account No. 50-3129. It is believed that no additional fee is required with this submission. However, should an additional fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-3129.

### **Certification Under 37 C.F.R. §1.97 (e)(2)**

Each item of information listed below this certification in this Supplemental Information Disclosure Statement was not cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, each item listed below was not known to any individual designated in § 1.56(c) more than three months prior to the filing of this Supplemental Information Disclosure Statement.

### **Publications**

FLEISCHER, et al., "Prescription of high-potency corticosteroid agents and clotrimazole-betamethasone dipropionate by pediatricians", *Clin. Ther.*, 21:1725-31 (1999)

HENGGE, et al., *J. Am. Acad. Dermatol.*, "Adverse effects of topical glucocorticosteroids", 54:1-15 (2006)

SHAFFER, et al., "Use of clotrimazole/betamethasone dipropionate by family physicians", *Fam. Med.*, 32:561-5 (2000)

SMITH, et al., "Nondermatologists are more likely than dermatologists to prescribe antifungal/corticosteroid products: an analysis of office visits for cutaneous fungal infections, 1990-1994", *J. Am. Acad. Dermatol.*, 39:43-47 (1998)

STERN, *J. Am. Acad. Dermatol.*, "The pattern of topical corticosteroid prescribing in the United States, 1989-1991", 35:183-6 (1996)

### Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

/ Patrea L. Pabst /

---

Patrea L. Pabst  
Reg. No. 31,284

Dated: May 21, 2007

PABST PATENT GROUP LLP  
400 Colony Square, Suite 1200  
1201 Peachtree Street  
Atlanta, Georgia 30361  
(404) 879-2151 (Telephone)  
(404) 879-2160 (Fax)